JP2001509168A - 血管新生を誘導するためのアデノウイルスベクターの多部位送達 - Google Patents
血管新生を誘導するためのアデノウイルスベクターの多部位送達Info
- Publication number
- JP2001509168A JP2001509168A JP53224998A JP53224998A JP2001509168A JP 2001509168 A JP2001509168 A JP 2001509168A JP 53224998 A JP53224998 A JP 53224998A JP 53224998 A JP53224998 A JP 53224998A JP 2001509168 A JP2001509168 A JP 2001509168A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- vector
- tissue
- target tissue
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013598 vector Substances 0.000 title claims abstract description 191
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 131
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 90
- 230000001939 inductive effect Effects 0.000 claims abstract description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 206010053648 Vascular occlusion Diseases 0.000 claims abstract description 16
- 239000003937 drug carrier Substances 0.000 claims abstract description 16
- 230000010412 perfusion Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 208000021331 vascular occlusion disease Diseases 0.000 claims abstract description 16
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 6
- 208000037906 ischaemic injury Diseases 0.000 claims abstract description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 68
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 67
- 210000002216 heart Anatomy 0.000 claims description 23
- 238000012217 deletion Methods 0.000 claims description 21
- 230000037430 deletion Effects 0.000 claims description 21
- 108700039887 Essential Genes Proteins 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 210000000056 organ Anatomy 0.000 claims description 10
- 230000008081 blood perfusion Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 140
- 241001465754 Metazoa Species 0.000 description 80
- 108090000623 proteins and genes Proteins 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 41
- 238000002347 injection Methods 0.000 description 37
- 239000007924 injection Substances 0.000 description 37
- 230000006870 function Effects 0.000 description 26
- 108010082117 matrigel Proteins 0.000 description 25
- 230000006698 induction Effects 0.000 description 24
- 230000000302 ischemic effect Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 210000004165 myocardium Anatomy 0.000 description 21
- 230000036961 partial effect Effects 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 210000003141 lower extremity Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000012546 transfer Methods 0.000 description 16
- 210000004351 coronary vessel Anatomy 0.000 description 15
- 238000001356 surgical procedure Methods 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 14
- 239000004005 microsphere Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 12
- 208000028867 ischemia Diseases 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 230000002107 myocardial effect Effects 0.000 description 11
- 230000008719 thickening Effects 0.000 description 11
- 230000002792 vascular Effects 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 210000000709 aorta Anatomy 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 102000058223 human VEGFA Human genes 0.000 description 9
- 230000002861 ventricular Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001746 atrial effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002603 single-photon emission computed tomography Methods 0.000 description 8
- 238000002583 angiography Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000002491 angiogenic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
- 230000002612 cardiopulmonary effect Effects 0.000 description 5
- 238000002592 echocardiography Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- JFRJCQJVFMHZOO-QZHHGCDDSA-N n-(2-aminoethyl)-2-[4-[[2-[4-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenyl]acetyl]amino]phenyl]acetamide Chemical compound C1=CC(CC(=O)NCCN)=CC=C1NC(=O)CC(C=C1)=CC=C1NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JFRJCQJVFMHZOO-QZHHGCDDSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 210000003752 saphenous vein Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000006427 angiogenic response Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000009434 installation Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000003872 anastomosis Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 108010011903 peptide receptors Proteins 0.000 description 3
- 102000014187 peptide receptors Human genes 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 238000002627 tracheal intubation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000008076 Angiogenic Proteins Human genes 0.000 description 2
- 108010074415 Angiogenic Proteins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 210000003090 iliac artery Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000001349 mammary artery Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- -1 more preferably Proteins 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000009707 neogenesis Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101710190943 Angiogenin-2 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010057751 Post procedural discharge Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- GDSCFOSHSOWNDL-UHFFFAOYSA-N Zolasepam Chemical compound N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F GDSCFOSHSOWNDL-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- IPSIPYMEZZPCPY-UHFFFAOYSA-N new fuchsin Chemical compound [Cl-].C1=CC(=[NH2+])C(C)=CC1=C(C=1C=C(C)C(N)=CC=1)C1=CC=C(N)C(C)=C1 IPSIPYMEZZPCPY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013175 transesophageal echocardiography Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229960001366 zolazepam Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3660197P | 1997-01-29 | 1997-01-29 | |
| US60/036,601 | 1997-01-29 | ||
| US08/801,352 | 1997-02-19 | ||
| US08/801,352 US5846225A (en) | 1997-02-19 | 1997-02-19 | Gene transfer therapy delivery device and method |
| US7115698P | 1998-01-13 | 1998-01-13 | |
| US60/071,156 | 1998-01-13 | ||
| PCT/US1998/001638 WO1998032859A1 (en) | 1997-01-29 | 1998-01-29 | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001509168A true JP2001509168A (ja) | 2001-07-10 |
| JP2001509168A5 JP2001509168A5 (https=) | 2005-09-08 |
Family
ID=27365066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53224998A Ceased JP2001509168A (ja) | 1997-01-29 | 1998-01-29 | 血管新生を誘導するためのアデノウイルスベクターの多部位送達 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6518255B2 (https=) |
| EP (1) | EP1012291B1 (https=) |
| JP (1) | JP2001509168A (https=) |
| KR (1) | KR20000070572A (https=) |
| AT (1) | ATE279518T1 (https=) |
| AU (1) | AU745409B2 (https=) |
| BR (1) | BR9806819A (https=) |
| CA (1) | CA2278621A1 (https=) |
| DE (1) | DE69827021T2 (https=) |
| HU (1) | HUP0001964A3 (https=) |
| IL (1) | IL131021A0 (https=) |
| MX (1) | MXPA99006993A (https=) |
| NO (1) | NO993669L (https=) |
| NZ (1) | NZ336838A (https=) |
| PL (1) | PL334902A1 (https=) |
| WO (1) | WO1998032859A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506911A (ja) * | 2013-01-17 | 2016-03-07 | メディツィーニシェ・ホーホシューレ・ハノーファーＭｅｄｉｚｉｎｉｓｃｈｅ Ｈｏｃｈｓｃｈｕｌｅ Ｈａｎｎｏｖｅｒ | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7238673B2 (en) | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| WO2001034208A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| AU745409B2 (en) * | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
| US6775574B1 (en) * | 1997-11-07 | 2004-08-10 | Medtronic, Inc. | Method and system for myocardial infarction repair |
| US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
| US6458092B1 (en) | 1998-09-30 | 2002-10-01 | C. R. Bard, Inc. | Vascular inducing implants |
| WO2000024415A2 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| WO2000047235A2 (en) * | 1999-02-10 | 2000-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of stimulating angiogenesis |
| US6986784B1 (en) | 1999-05-14 | 2006-01-17 | C. R. Bard, Inc. | Implant anchor systems |
| US6440945B1 (en) * | 1999-05-27 | 2002-08-27 | Instituto Dermopatico Dell'immacolata | Method of inducing angiogenesis in nonis chemic skeletal muscle |
| AU5624400A (en) * | 1999-06-18 | 2001-01-09 | Collaborative Group, Ltd., The | Hyaluronic acid film and matrix for sustained gene transfer |
| EP1067190A1 (en) * | 1999-07-09 | 2001-01-10 | Introgene B.V. | Gene therapy for enhancing and/or inducing angiogenesis |
| US6855160B1 (en) | 1999-08-04 | 2005-02-15 | C. R. Bard, Inc. | Implant and agent delivery device |
| CA2378250A1 (en) | 1999-08-05 | 2001-02-15 | Todd K. Rosengart | Gene therapy platformed needle and method of administering a therapeutic solution to a heart |
| FR2799465B1 (fr) * | 1999-10-12 | 2004-02-13 | Centre Nat Rech Scient | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire |
| US6329348B1 (en) * | 1999-11-08 | 2001-12-11 | Cornell Research Foundation, Inc. | Method of inducing angiogenesis |
| US7232421B1 (en) | 2000-05-12 | 2007-06-19 | C. R. Bard, Inc. | Agent delivery systems |
| US6508802B1 (en) | 2000-05-23 | 2003-01-21 | Cornell Research Foundation, Inc. | Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart |
| US7204847B1 (en) | 2000-07-28 | 2007-04-17 | C. R. Bard, Inc. | Implant anchor systems |
| US6939540B1 (en) | 2000-07-31 | 2005-09-06 | Cornell Research Foundation, Inc. | Method of enhancing bone density |
| JP2004505619A (ja) * | 2000-08-04 | 2004-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮増殖因子２ |
| US20040009940A1 (en) * | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
| EP1330252A4 (en) * | 2000-11-01 | 2007-12-26 | Ludwig Inst Cancer Res | IN VIVO STIMULATION OF ANGIOGENIC ACTIVITY |
| EP1361896A2 (en) * | 2001-01-23 | 2003-11-19 | Boston Scientific Corporation | Localized myocardial injection method for treating ischemic myocardium |
| AR027161A1 (es) * | 2001-05-15 | 2003-03-19 | Bio Sidus S A | Metodo para inducir la proliferacion neovascular y regeneracion tisular |
| US20030157064A1 (en) * | 2001-11-09 | 2003-08-21 | Pascal Neuville | Chimeric promoters for controlling expression in muscle cells |
| AU2003291526A1 (en) * | 2002-11-15 | 2004-06-15 | Genvec, Inc | Coronary artery disease treatment |
| EP2289534B1 (en) | 2004-04-05 | 2017-08-30 | The Regents of The University of California | NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| RU2321631C2 (ru) * | 2005-06-24 | 2008-04-10 | Государственное учреждение Российский научный центр хирургии РАМН | Неинфекционный для человека аденовирус как вектор для заместительной генной терапии нарушений ангиогенеза, обеспечивающий эффективный синтез ангиогенина человека в трансфецированных клетках млекопитающих, способ индукции ангиогенеза, способ лечения ишемической болезни, композиция для индукции ангиогенеза и лечения ишемической болезни |
| US7751883B2 (en) | 2006-04-25 | 2010-07-06 | Eugenio Picano | System and method for promoting coronary angiogenesis |
| US9598673B2 (en) * | 2006-05-19 | 2017-03-21 | Creative Medical Health | Treatment of disc degenerative disease |
| US8983570B2 (en) | 2007-03-27 | 2015-03-17 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treatment of the spine |
| US11224635B2 (en) | 2007-03-27 | 2022-01-18 | Venturis Thereuptics, Inc. | Therapeutic angiogenesis for treatment of the spine and other tissues |
| EP2612867A1 (en) | 2007-11-01 | 2013-07-10 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| US8409147B2 (en) * | 2009-08-22 | 2013-04-02 | Joseph Wayne Kraft | Rapid local anesthesia linear injection device |
| US8088108B2 (en) * | 2009-08-22 | 2012-01-03 | Joseph Wayne Kraft | Rapid local anesthesia injection cone |
| WO2011026041A2 (en) | 2009-08-28 | 2011-03-03 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
| WO2014036222A1 (en) * | 2012-08-30 | 2014-03-06 | Emory University | Systems, methods and computer readable storage media storing instructions for integrating fluoroscopy venogram and myocardial images |
| EP3259346B1 (en) | 2015-02-20 | 2024-08-07 | Baylor College of Medicine | P63 inactivation for the treatment of heart failure |
| MX388822B (es) | 2016-12-05 | 2025-03-20 | Nuritas Ltd | Composiciones que comprenden peptido wkdeagkplvk. |
| EP3329930A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmaceuctical compositions |
| EP4041192A4 (en) * | 2019-10-09 | 2023-11-08 | Xylocor Therapeutics, Inc. | EPICARDIAL GENE THERAPY DELIVERY |
| WO2024233783A1 (en) | 2023-05-09 | 2024-11-14 | Cornell University | Expression cassette coding for vascular endothelial growth factor |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US510413A (en) | 1893-12-12 | Drainage-tube | ||
| US2551902A (en) | 1948-09-10 | 1951-05-08 | Arthur Schaffer | Dehorning fluid ejector |
| US2670673A (en) | 1950-07-17 | 1954-03-02 | Joyce A Gordon | Fluid injecting device |
| US3467096A (en) | 1966-04-12 | 1969-09-16 | Ferrell S Horn | Multiple hypodermic syringe arrangement |
| FR1584474A (https=) | 1968-02-20 | 1969-12-26 | ||
| US3572336A (en) | 1968-04-30 | 1971-03-23 | Daniel R Hershberg | Syringe |
| US4150669A (en) | 1977-03-16 | 1979-04-24 | Alvaro Latorre | Apparatus for effecting and enhancing an erection |
| US4167179A (en) | 1977-10-17 | 1979-09-11 | Mark Kirsch | Planar radioactive seed implanter |
| US5335670A (en) | 1986-04-18 | 1994-08-09 | Henry Fishman | Allergy testing method and apparatus |
| JPS6438100A (en) | 1987-07-31 | 1989-02-08 | Toray Industries | Vascular endothelial cell growth factor |
| JPH02117698A (ja) | 1988-10-27 | 1990-05-02 | Toray Ind Inc | 血管内皮細胞成長因子 |
| US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
| JPH02279698A (ja) | 1989-04-20 | 1990-11-15 | M K Medical:Kk | 血管内皮細胞成長因子及びその製造方法 |
| US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| DE69024261T2 (de) | 1989-05-24 | 1996-07-18 | Merck & Co Inc | Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors |
| US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| JPH03178996A (ja) | 1989-12-06 | 1991-08-02 | Makoto Goto | 成長因子 |
| US6228844B1 (en) * | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| EP0476983B1 (en) | 1990-09-21 | 2000-03-15 | Merck & Co. Inc. | Vascular endothelial cell growth factor II |
| EP0506477B1 (en) | 1991-03-28 | 1999-06-23 | Merck & Co. Inc. | Vascular endothelial cell growth factor C subunit |
| US5244460A (en) | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
| EP0550296A3 (en) | 1991-11-28 | 1993-12-29 | Terumo Corp | Vascular endothelial cells growth factor |
| US5290258A (en) | 1992-07-27 | 1994-03-01 | Genesis Industries, Inc. | Syringe for administering sequentially multiple doses of a medicament |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| EP0751992B1 (en) | 1994-03-08 | 2005-11-09 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US5417683A (en) | 1994-07-13 | 1995-05-23 | Shiao; I-Shen | Mini-graft hair implanting device for implanting multiple clumps of hair follicles at one time |
| WO1996012406A1 (en) * | 1994-10-19 | 1996-05-02 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
| US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| JP3178996B2 (ja) | 1995-08-24 | 2001-06-25 | 沖電気工業株式会社 | カード処理装置及びカード送り速度の制御方法 |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
| AU745409B2 (en) * | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
| JP3371331B2 (ja) * | 1998-12-14 | 2003-01-27 | セイコーエプソン株式会社 | インクジェット式記録ヘッドおよびその製造方法 |
-
1998
- 1998-01-29 AU AU62530/98A patent/AU745409B2/en not_active Ceased
- 1998-01-29 KR KR1019997006818A patent/KR20000070572A/ko not_active Withdrawn
- 1998-01-29 CA CA002278621A patent/CA2278621A1/en not_active Abandoned
- 1998-01-29 AT AT98904730T patent/ATE279518T1/de not_active IP Right Cessation
- 1998-01-29 JP JP53224998A patent/JP2001509168A/ja not_active Ceased
- 1998-01-29 MX MXPA99006993A patent/MXPA99006993A/es unknown
- 1998-01-29 IL IL13102198A patent/IL131021A0/xx unknown
- 1998-01-29 PL PL98334902A patent/PL334902A1/xx unknown
- 1998-01-29 NZ NZ336838A patent/NZ336838A/en unknown
- 1998-01-29 BR BR9806819-9A patent/BR9806819A/pt not_active IP Right Cessation
- 1998-01-29 DE DE69827021T patent/DE69827021T2/de not_active Expired - Fee Related
- 1998-01-29 EP EP98904730A patent/EP1012291B1/en not_active Expired - Lifetime
- 1998-01-29 WO PCT/US1998/001638 patent/WO1998032859A1/en not_active Ceased
- 1998-01-29 HU HU0001964A patent/HUP0001964A3/hu unknown
-
1999
- 1999-07-19 US US09/357,010 patent/US6518255B2/en not_active Expired - Lifetime
- 1999-07-28 NO NO993669A patent/NO993669L/no not_active Application Discontinuation
-
2003
- 2003-01-14 US US10/341,679 patent/US20030103943A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506911A (ja) * | 2013-01-17 | 2016-03-07 | メディツィーニシェ・ホーホシューレ・ハノーファーＭｅｄｉｚｉｎｉｓｃｈｅ Ｈｏｃｈｓｃｈｕｌｅ Ｈａｎｎｏｖｅｒ | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2020203894A (ja) * | 2013-01-17 | 2020-12-24 | メディツィーニシェ・ホーホシューレ・ハノーファーＭｅｄｉｚｉｎｉｓｃｈｅ Ｈｏｃｈｓｃｈｕｌｅ Ｈａｎｎｏｖｅｒ | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2023025005A (ja) * | 2013-01-17 | 2023-02-21 | メディツィーニシェ・ホーホシューレ・ハノーファー | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000070572A (ko) | 2000-11-25 |
| MXPA99006993A (es) | 2005-06-01 |
| NO993669D0 (no) | 1999-07-28 |
| EP1012291A1 (en) | 2000-06-28 |
| AU745409B2 (en) | 2002-03-21 |
| US6518255B2 (en) | 2003-02-11 |
| ATE279518T1 (de) | 2004-10-15 |
| EP1012291B1 (en) | 2004-10-13 |
| DE69827021T2 (de) | 2005-02-24 |
| IL131021A0 (en) | 2001-01-28 |
| CA2278621A1 (en) | 1998-07-30 |
| HUP0001964A2 (hu) | 2000-10-28 |
| US20030103943A1 (en) | 2003-06-05 |
| DE69827021D1 (de) | 2004-11-18 |
| AU6253098A (en) | 1998-08-18 |
| NZ336838A (en) | 2002-04-26 |
| BR9806819A (pt) | 2000-05-09 |
| PL334902A1 (en) | 2000-03-27 |
| HUP0001964A3 (en) | 2002-01-28 |
| NO993669L (no) | 1999-09-27 |
| US20010041679A1 (en) | 2001-11-15 |
| WO1998032859A1 (en) | 1998-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001509168A (ja) | 血管新生を誘導するためのアデノウイルスベクターの多部位送達 | |
| JP3961019B2 (ja) | 遺伝子転移媒介の血管形成療法 | |
| EP1017421B1 (en) | Use of adenoviral vectors expressing VEGF or PDGF FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE | |
| EP1232759A1 (en) | Gene transfer-mediated angiogenesis therapy | |
| US20160250290A1 (en) | Gene therapy for diabetic ischemic disease | |
| AU2017277277B2 (en) | Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto | |
| Funatsu et al. | Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor | |
| US6329348B1 (en) | Method of inducing angiogenesis | |
| JP2002502885A (ja) | 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ | |
| Iwatate et al. | Effects of in vivo gene transfer of fibroblast growth factor-2 on cardiac function and collateral vessel formation in the microembolized rabbit heart | |
| US20050191278A1 (en) | Coronary artery disease treatment | |
| Cai et al. | Cationic microbubble loading hSIRT3 and hTIMP3 optimize cardiac-targeted delivery and myocardial protection in the porcine MI/R model | |
| WO2011024480A1 (ja) | 血管新生療法用医薬組成物 | |
| Banai et al. | Cellular and Molecular Cardiology: Angiogenic-Induced Enhancement of Collateral Blood Flow to Ischemic Myocardium by Vascular Endothelial Growth Factor in Dogs | |
| HK1008979B (en) | Gene transfer-mediated angiogenesis therapy | |
| AU2006235836A1 (en) | Gene transfer-mediated angiogenesis therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080826 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081014 |